Rapid detection of soluble F1 capsular antigen in serum, bubo fluid or urine of patients proved to be a valuable tool in the presumptive diagnosis of plague.
Introduction
The laboratory diagnosis of clinically suspected plague is based on bacteriological and serological methods [1] . But isolation of Yersinia pestis is often hampered as most patients are readily treated empirically with antibiotics due to the acute and severe presentation of the disease before biological samples are taken or sampling and transport of clinical specimens in rural areas of endemic countries are inadequate [2, 3] . Detection of Y. pestis-specific antibodies is used to retrospectively confirm the diagnosis in human cases, to estimate efficacy of vaccination against plague or to survey enzootic plague foci [4] [5] [6] . Besides the passive haemagglutination assay (PHA), which has repeatedly shown to lack sensitivity and specificity [7, 8] , rapid and reliable techniques are now available for endemic and non-endemic areas [2, 8, 9] .
However, neither cultivation nor serological testing is well suited for the management of acute plague patients due to the time delay until reliable results are available. Therefore rapid assays based on the detection of Y. pestis-specific antigens or nucleotide sequences were developed allowing a presumptive diagnosis of acute plague [1, [10] [11] [12] . Whereas sensitive PCR-based detection methods have been described to identify Y. pestis strains after cultivation, in spiked samples of fleas or from experimentally infected animals [13] [14] [15] , the diagnostic value of PCR under field conditions has shown to be doubtful due to its low sensitivity as compared to culture or F1 capsular antigen (F1 CA) detection [16] .
In contrast to the molecular approach, in vitro detection of F1 CA by immunoassays employing anti-F1 CA monoclonal antibodies were repetitively demonstrated as valuable tools in early diagnosis and for surveillance of plague [6] [7] [8] 12] . Immunogold chromatographic dipstick assays and an ELISA displayed 100% specificity on different specimens including serum, urine and bubo fluid. Sensitivity was 98% or 100%, respectively, when they were used on bubo aspirate [17] .
Immunochromatographic assays are rapid and easy to perform. For this reason they might be well suited under field conditions, when a presumptive diagnosis based on a qualitative detection of F1 CA is needed. But for the handling of a large number of samples and for a reliable quantification of F1 antigenaemia, which might be even used as a prognostic marker [18] , ELI-SA formats would be more appropriate and less expensive.
However, no standardized ELISA test kit for the quantitative analysis of F1 CA in human serum is currently commercially available or has been sufficiently developed to be used in routine clinical laboratories in endemic or in non-endemic areas.
This lack is of particular concern for clinicians, clinical microbiologists and public health authorities in nonendemic areas. In these countries, rapid confirmation or exclusion of plague in severely ill patients returning from endemic areas is mandatory. Detection of F1 CA in serum of suspected plague cases would have a major impact on case management, anti-infectious and supportive treatment, isolation of the patient and contacts as well as general epidemic measures to prevent the spread of this highly communicable disease.
In this work we describe the evaluation of a standardized F1 capsular antigen capture ELISA test kit suitable for the rapid diagnosis of human plague.
Materials and methods

F1 CA capture ELISA
Recently, a quantitative capture ELISA employing a commercially available monoclonal antibody (mAb) directed against F1 CA (YPF19 IgG1, Biotrend, Cologne, Germany) was established in our laboratory [19] . This ELISA was modified and manufactured by a biotechnology company (Seramun, Dolgenbrodt, Germany).
The test kit included the following materials: 12 single strips with 8 microwells each, coated with anti-F1 CA mAb ( For the quantitative analysis of human serum samples, the ELISA was carried out using standard protocols. Briefly, 50 ll of serum diluent were added to the wells. Then, 50 ll of the sample, standards S1-S5 and both controls (F1 CA positive control, dilution buffer as negative control) were added into the wells. Standards and controls were performed in duplicates. The strips were incubated for 60 min at 37°C. After washing five times with 1Â washing buffer, 100 ll HRP anti-F1 CA conjugate (concentrate, diluted 1:101 in serum diluent) were added to each well. The strips were again incubated for 60 min at 37°C. After an identical washing step, 100 ll TMB/H 2 O 2 substrate was pipetted into each well and allowed to incubate for further 15 min at room temperature. The enzymatic reaction was stopped by adding 100 ll sulphuric acid per well. Within the next 15 min the absorbance was read at 450 nm wavelength.
The validity of each performed test was controlled according to the following criteria:
• Absorbance standard S1 (25 ng ml À1 ): P 1.500.
• Absorbance negative control (diluent): 6 0.150.
• Absorbance standard S4 < absorbance positive control < absorbance standard S3. By plotting the measured absorbancies (y-axis) versus the corresponding standard concentrations S1-S5, a standard curve was created for each test, which was used to convert the absorbancies of the samples into ng F1 CA ml À1 . Samples of the negative control group showing an absorbance above 0.215 were re-evaluated using a confirmatory assay by means of specific antibody neutralization. These sera were retested with a modified assay. Antibody to F1 CA (10 lg ml À1 ) was incubated with a reactive sample. Standards, controls and reactive sera were tested in parallel in the presence or absence of the neutralizing antibody using microwells from a single test kit. All assays were performed in duplicates. The ratio of the mean absorbance without inhibition and the signal obtained in the presence of the neutralizing antibody was calculated for the positive controls and all reactive sera of the negative group. The significance of the difference between the ratios of both groups was demonstrated by performing a one-tailed Student's t test.
Bacteriological testing
Bacteriology is the gold standard assay for plague. Bubo aspirates obtained during the 1998 outbreak of plague in the harbor of Mahajanga, Madagascar, were examined for growth of Y. pestis using standard bacterial cultivation as described elsewhere [20] . Additionally, smears from bubo samples were examined microscopically after Wayson's staining [20] .
The concordance of bacteriological testing and detection of F1 antigen by ELISA was analyzed employing the chi-square test.
Test sera and specimens
Intra-assay variance was determined by the manufacturer (Seramun, Dolgenbrodt, Germany) directly before the test kits were distributed. Herein five F1 CA preparations ranging from 6.25 to 20 ng ml À1 , resuspended in FCS, were used. Inter-assay variance was investigated employing the standard antigen preparations distributed with the test kit. To determine the specificity of the ELISA, 47 sera from healthy Malagasy individuals were examined. The cutoff was calculated as mean absorbance + 3 Â the standard deviations (SD) of these 47 sera (OD 450 nm ¼ 0.215) thereby defining a minimum detectable F1 CA concentration of 4 ng ml À1 . To ensure that this empirically calculated F1 CA concentration has a statistically significant difference from the response of zero analyte samples, a one-tailed Student's t test was performed employing the negative (0.0 ng F1 CA ml À1 ) and positive controls (3.12 ng F1 CA ml À1 ) of the test kits. Additionally, 365 sera from blood donors, collected in 1998 at the Armed Forces Medical Academy, Germany, were tested. A total of 92 bubo aspirates and 35 serum samples from patients presumed to suffer from acute plague, were analyzed for the presence of F1 CA. Samples were taken prior treatment.
Statistics
Calculations and correlation analyses were performed to prove the validity of the presented data employing the R 1.7.1 software package which is freely available at www.r-project.org.
Results
Detection time, validity and standard curve
The application of the F1 CA capture ELISA test kit allowed the quantitative detection of F1 CA in sera and bubo aspirates from plague patients within 2.5 h. Eighty-two samples could be examined simultaneously. The validity of each test format was confirmed using the internal controls and standards. By applying the corresponding standard curve, the absorbance of each sample could be converted into the F1 CA concentration contained in the sample. Specimens with more than 25 ng F1 CA ml À1 had to be re-evaluated using various dilutions. The mean absorbance for the positive control (3.12 ng F1 CA ml À1 ) was 0.152 (SD 0.008, n ¼ 5), which was significantly different from the mean absorbance of the negative control (0.046, SD 0.009, n ¼ 5; p < 0:01).
Intra-and inter-assay variance
To demonstrate the intra-assay variance, serum was spiked with F1 CA employing five different concentrations and repetitively tested using strips from a single test kit. The coefficient of variation ranged from 3.21 to 6.41% ðn ¼ 16Þ. The inter-assay variance was determined by repeating the assay at five different days by the same investigator. These experiments were performed in parallel at the Institute Pasteur (WHO collaborating laboratory) in Antananarivo, Madagascar and at the Institute of Microbiology in Munich, Germany. The coefficient of variation for F1 CA concentrations above the cut-off value varied between 5 and approximately 10% (Table 1) .
Test specificity and sensitivity
The specificity was 100% for the evaluation in Antananarivo, Madagascar, where 47 samples were tested. In Germany, 365 sera were investigated. In this group with no known history of plague infection or vaccination against Y. pestis, six sera were repetitively tested positive, resulting in a primary test specificity of 98.4%. When the confirmatory assay was performed with the positive controls and standards included in the test kit (which are spiked serum samples), reduction of specific signals ranged from 65.5% to 75.0%. Two reactive serum samples from healthy blood donors showed no inhibition, which confirmed that the positive signal in these samples was not specific. For the other 4 sera, signal reduction ranged only from 12.8% to 47.4% (Table 2) .
In Antananarivo, serum samples from 35 clinical suspected plague cases were tested for the presence of F1 CA. In 11 patients the diagnosis was definitively confirmed by growing the causative agent from bubo aspirates. Circulating F1 CA was detected in the serum of 10 of these patients resulting in a sensitivity of 90.1% for the ELISA.
Additionally, in two samples a positive signal occurred in the ELISA although in these patients bacteriology did not reveal Y. pestis. In 22 samples, bacteriology and the F1 CA capture ELISA were both negative.
When the cut-off established for serum samples was employed on material aspirated from buboes, all 18 specimens from Y. pestis-positive patients and three from subjects with presumptive plague diagnosis were found positive for F1 CA (Table 3) .
Additionally, 13 buboes were positive for F1 CA although microscopy and cultivation for Y. pestis were negative for these samples. In two of these 13 patients, plague specific antibodies were later found in convalescent serum, three were serologically negative, for 8 patients no additional information was available. Further on, 57 bacteriologically negative samples were also negative in the F1 CA capture ELISA (Table 3 ).
Discussion
Plague is an acute and life-threatening disease, which is also highly communicable if secondary pneumonic plague develops from untreated bubonic cases [21] . Detection of F1 capsular antigen, an antigen unique to Y. pestis, has been used for a presumptive diagnosis of plague in human patients and in infected animals [8, 22] .
In a retrospective study, the application of an ELISA to demonstrate F1 CA antigenaemia resulted in 20% increase in laboratory confirmation of plague compared to culture and PHA [8] . Measurement of soluble F1 CA in blood, urine, sputum or bubo aspirate proved to be a valuable tool in rapid diagnosis and management of bubonic and pneumonic plague [17, 21] . Additionally, quantitative analysis and follow-up of F1 CA antigenaemia might be helpful regarding prognosis and monitoring efficacy of the current therapy scheme [18] . This application is of increasing clinical relevance as multi-resistant Y. pestis strains have been recently isolated [23, 24] . Samples of the negative control group showing an absorbance above 0.215 were re-evaluated using a confirmatory assay by means of specific antibody neutralization. Controls and reactive sera were tested in parallel in the presence or absence of the neutralizing antibody (anti-F1 CA mAk, 10 lg ml À1 ) using microwells from a single test kit. All six reactive serum samples showed either no inhibition or a significantly diminished (12.8-47.4%) signal reduction compared to the reduction of the positive controls ðp < 0:001Þ.
a All assays were performed in duplicates. b HBD, healthy blood donor. c No inhibition. Table 3 Comparison of F1 CA detection with cultivation of Y. pestis in 92 bubo specimens from clinically suspected plague cases The ELISA procedures published so far demonstrated high sensitivity and specificity, but they represent only in-house tests, built up and evaluated in specialized laboratories. Even a more standardized dipstick assay is not yet readily commercially available [17] .
The aim of this study was further evaluation of a ready-to-use test kit for the detection of F1 CA produced under the standards of a commercial manufacturer. This test kit had been tested in a round robin trial in ten German routine laboratories proving its applicability, stability and reproducibility [25] .
We were able to confirm the reproducibility of the test kit under laboratory conditions of a plague endemic country. The coefficient of variation ranged from 5% to 10% regarding intra-day as well as inter-day variance. The total assay time was only 2.5 h for 82 samples compared to 5 h for recently employed ELISA protocols [17] . This might represent a significant improvement because timely adequate treatment in acute plague is essential in saving the lives of the affected patients and rapid identification and isolation of new cases will reduce the spread of the causative agent.
The specificity of the standardized test kit was 100% in healthy Malagasy subjects (endemic area) and 98.4% within a group of German blood donors. In an outbreak situation providing a high prevalence of plague, this specificity will be acceptable.
A few false-positive results occurred with the ELISA when many samples from a non-endemic area were tested. This may be due to cross-reactivity of serum components, which are recognized by the rabbit anti-F1 conjugate or may be based on the presence of heteroantibodies or anti-animal antibodies cross-linking the conjugate to the microwells [26] . Finding two reactive sera that showed no inhibition in the confirmatory assay supports this hypothesis. In the other sera, only a moderate to weak reduction of the absorbance occurred, which differed significantly from the inhibition seen with the standards. Though the presented confirmatory assay awaits further evaluation, it might prove to be a valuable tool for increasing test specificity to virtually 100% by rapidly ruling out false-positives.
At the detection limit of 4 ng F1 CA ml À1 serum, test sensitivity was 90.1% for serum samples. Regarding this distinct outbreak, the application of the F1 CA ELISA would have resulted in an early substantiation of the clinical diagnosis in 10 out of 11 patients.
For bubonic plague, it was recently shown that direct examination of bubo aspirates is superior to the application of serum or urine specimens [17] . When the test kit, originally developed and evaluated for using serum specimens, was applied on bubo aspirates F1 CA was detected in all 18 culture-positive bubo specimens.
While testing 92 bubo fluids, 16 culture-negative samples reacted in the ELISA. Whether these results represent false positives of the ELISA or just mirror the repetitively described lack of sensitivity of bacteriological cultivation, caused by inadequate sampling and transportation, contamination or self-medication prior to hospitalization [2, 3, 17] , has to be clarified.
It might be necessary to determine a distinctive cutoff of the F1 CA capture ELISA for bubo samples by examining specimens from patients suffering from different infections associated with acute lymphadenitis. A separate evaluation of the test kit is also necessary for the analysis of other sample matrices like tissues (postmortem specimens), materials derived from rodents, or bacterial isolates obtained by cultivation.
In bubonic plague, the presumptive diagnosis is often made clinically, particularly in endemic areas. Due to the assumed high bacterial burden in the affected lymph nodes, it is reasonable to use bubo aspirates as primary specimen. F1 CA concentration within the lymph node might exceed the serum level by several orders of magnitude, especially if the disease has not yet progressed towards a systemic infection. Nevertheless, we decided to standardize and evaluate the test kit on human serum specimens for several reasons. The most dangerous clinical presentations of plague are primary pneumonic and septicemia cases, where no bubos are present. In non-endemic areas, bubonic plague might not be considered as first line diagnosis and therefore bubo aspirate will not be obtained in early stages. And apart from that, serum is the body fluid that is assayed most frequently because it is most accessible, independently where the test kit is applied.
One major drawback of the test format is the low dynamic range of the assay (1-25 ng ml À1 ). The test was principally developed for the sensitive detection of small amounts of F1 CA. However, this investigation and other studies revealed that high levels of F1 CA (several lg ml À1 ) can occur in patients [12, 18] . To avoid timeconsuming and costly re-testing of positive samples using various serum dilutions, the dynamic range should be expanded to at least 1 lg ml À1 F1 CA. As described in previous studies and confirmed in this work, neither cultivation nor serological testing nor detection of F1 CA alone allow the definite exclusion of clinical suspected 'plague'. A critical gap can occur in the first few days after the onset of clinical symptoms. At this time antibody production has not started yet and cultivation of the causative agent is often hampered or delayed due to starting of an empirically based antibiotic regime. Especially in this clinical setting, the detection of soluble F1 CA indicating an acute infection with Y. pestis could prove to be most valuable. Nevertheless, the F1 CA ELISA has to be combined with a serological assay for antibody detection because the rise of specific antibodies will rapidly prevent further detection of circulating F1 CA [8] . For resistance testing, for genomic typing and for surveillance of Y. pestis in endemic areas, the causative agent still has to be cultivated. The detection of F1 CA should be used complementary to the currently employed methods to improve the laboratory diagnosis of plague. For routine application of F1 CA detection, especially in microbiological laboratories with no expertise in plague diagnosis, a standardized and commercially available test kit might be well suited.
Y. pestis strains lacking a classical F1 capsule have been described [27] [28] [29] . These strains will escape a diagnosis based only on the presence of F1 CA. But the natural occurrence of those strains seems to be very rare. A reduced expression rather than the total loss of the F1 CA gene (caf1) is more likely [27] . However, the repetitive isolation of F1 CA-negative strains from other sources and the possibility of creating caf1-negative mutants by genetic manipulation [30] , makes it necessary to develop additional diagnostic tools. A few procedures using either a panel of specific monoclonal antibodies to other prominent antigens of Y. pestis [31, 32] or the combination of PCR assays targeting different genes have already been described [15] .
